

RMS Cheat Sheet

Site:

Favorable	Unfavorable
Vagina	Bladder
Uterus	Prostate
Vulva	Urachal
Paratestis	Retroperitoneal

Stage:

- Uses site + TNM system
- Clinical at time of diagnosis, with histologic confirmation of RMS
- **Before** surgical intervention
- Assigned by surgeon

Stage	GU site	T	Size	N	M
I	Female genital tract Paratestis	Any	Any	Any	M0
II	BP only	Any	a	N0 or Nx	M0
III	BP only	Any	a b	N1 N0 or N1 or Nx	M0
IV	All	Any	Any	Any	M1

Notes:

- T1 confined to anatomic site of origin
 T2 extension and/or fixation to surrounding tissue
 a <5cm
 b >5cm
- Nx regional LNs not evaluated
 N0 regional LNs not involved
 N1 regional LNs involved
- M0 no distant mets
 M1 distant mets

BP = unfavorable site → cannot be stage I

Paratestis/female genital tract = favorable site → can only be stage I or IV

Group:

- Based on pathologic histologic diagnosis
- **After** surgical intervention
- **Before** chemotherapy begins

Group	Description
I	Localized disease, completely resected, no LN involvement
a	Confined to organ of origin
b	Contiguous involvement (infiltration through organ of origin)
II	Total gross resection with regional spread
a	Microscopic residual, LN- (+margin and LN-)
b	No microscopic residual, LN+ (-margin and LN+)
c	Microscopic residual, LN+ (+margin and +LN with most distal LN+)
III	Incomplete resection with gross residual disease
a	Biopsy only
b	Gross resection of >50% of tumor (debulking)
IV	Distant mets
Notes:	
<ul style="list-style-type: none"> Regional LN biopsy/sampling for group I patients is highly advised if easily feasible LN's taken with specimen must be examined and if + → group IIb or higher For paratestis, cN1 disease OR age >10y → ipsi RPLND 	

Histology:

- Embryonal = fusion neg
 - Botryoid, spindle cell are even more favorable
 - More favorable outcomes
- Alveolar = fusion pos
 - PAX/FOXO1 fusion pos
 - Less favorable outcomes

Clinical risk group

Risk category	Stage	Group	Fusion	3y failure-free survival
Low ARST 2032	I	I	neg	88%
	II	I		
	II	II		
	III	I		
	III	II		
Intermediate ARST 1431	II, III	I, II, III	pos	55-76%
	II, III	III	neg	
High ARST 2031	IV	IV	pos	<30%
	IV	IV	neg	

PRE → pre-treatment re-excision (complete R0 excision before chemotherapy)

DPE → delayed primary excision (consolidate with surgery instead XRT)